Ernexa (ERNA) news

Ernexa Therapeutics CEO Corner highlights appointment of Dr. Robert J. Spiegel as company sharpens oncology focus and advances ERNA-101 toward the clinic

Ernexa Therapeutics (NASDAQ: ERNA) has announced the appointment of Dr. Robert J. Spiegel to its leadership team as the company continues to sharpen its focus on oncology and advance its lead cell therapy candidate, ERNA-101, toward clinical development. The move comes as the company prepares for a…

Ernexa Therapeutics appoints accomplished biopharmaceutical executive Robert J. Spiegel, M.D., FACP, to board of directors

Ernexa Therapeutics Inc. (NASDAQ: ENXA) has announced the appointment of Robert J. Spiegel, M.D., FACP, to its board of directors, effective immediately [1]. Dr. Spiegel brings over two decades of leadership experience in the biopharmaceutical industry, having previously held executive roles at…

Ernexa Therapeutics - Intends to broaden oncology program and advance next-generation IMSC candidates

Ernexa Therapeutics - Plans ERNA-101 ind submission in Q4 2026

Ernexa Therapeutics (NASDAQ: ERNA) has outlined its plans to submit an Investigational New Drug (IND) application for its lead candidate, ERNA-101, in the fourth quarter of 2026, according to recent developments. The company has successfully completed process development for ERNA-101 and is now…

Ernexa Therapeutics - Clinical data from ERNA-101 proc study expected in Q4 2027

Ernexa Therapeutics (ERNX) announced that clinical data from its Phase II study of ERNA-101, a novel RNA-based therapeutic candidate, is expected to be released in the fourth quarter of 2027. The study, which is evaluating the safety, tolerability, and preliminary efficacy of ERNA-101 in patients…